Pregabalin Capsule
Product Images NDC 68788-7520

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-7520). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Capsules 25mg (cv) (Pregabalin Caps 25mg 30ct)

Label for Pregabalin Capsules 25 mg by Preferred Pharmaceuticals, Inc. The label indicates the product is generic for Lyrica, with each capsule containing 25 mg pregabalin. It includes storage instructions, a barcode, manufacturer information (ScieGen Pharmaceuticals, Inc.), and dosing directions in English and Spanish. The label also features a caution about federal law prohibiting drug transfer.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and a placebo group. The graph shows trends of patient improvement across these dosages.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph depicting the percentage of patients improved versus the percent improvement in pain from baseline. The graph compares Pregabalin 100 mg three times a day to a placebo, showing patient improvement trends across different pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice daily, as well as a placebo group. The graph shows trends of patient improvement at varying pain reduction thresholds up to 100%.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. Three lines compare outcomes for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph highlights higher patient improvement with increased Pregabalin doses compared to placebo.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph illustrating the percent improvement in pain from baseline versus the percent of patients who improved. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. Each group is represented by a distinct line style, showing differences in patient improvement over a range of percentage values.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) in Studies E1 and E3 for various Pregabalin dosages versus placebo. The chart shows increasing responder rates with higher dosages, marked with asterisks indicating statistical significance versus placebo. Study E1 includes dosages from 50 mg/day to 600 mg/day, Study E3 shows 300 mg/day and 600 mg/day with different dosing schedules.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph illustrating seizure reduction (median % change from baseline) versus dose (mg/day) for four different studies identified as E1 BID, E2 TID, E3 BID, and E3 TID. The graph shows significant increases in seizure reduction with increasing dose, with p-values indicating statistical significance at multiple dose points. The dose 0 represents placebo.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line chart displaying the percent of patients improved versus percent improvement in pain from baseline for Pregabalin doses (300 mg, 450 mg, 800 mg daily) compared to placebo. Four lines represent each treatment group, showing trends of patient improvement in pain relief across increasing percentages of pain reduction.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve comparing Pregabalin and placebo over 180 days. The y-axis shows the estimated percentage of subjects without LTR, and the x-axis represents time in days. The solid line represents Pregabalin, and the dashed line represents placebo, with Pregabalin showing a higher estimated percentage of subjects without LTR throughout the period.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time from baseline to Week 12 for Pregabalin versus placebo. The horizontal axis represents percent improvement from baseline, and the vertical axis shows the percent of subjects improved. Two lines depict the performance difference between Pregabalin (solid line) and placebo (dotted line).*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing percent of subjects improved on Pregabalin versus Placebo over weeks, showing percent improved from baseline to Week 16 on the x-axis and percent of subjects improved on the y-axis. The graph illustrates higher improvement rates for Pregabalin compared to Placebo.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

An equation panel showing the formula for calculating creatinine clearance (CLcr). The formula is CLcr equals the product of the difference between 140 and age in years multiplied by weight in kilograms, divided by 72 times serum creatinine in mg/dL, with a multiplier of 0.85 for female patients. This panel provides a calculation relevant to dosing or pharmacokinetic considerations.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin, showing its molecular formula representation with an amino group, carboxyl group, and hydrocarbon backbone.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.